Kate handles a diverse portfolio of technologies in the life sciences and biopharmaceutical fields, including antibody and peptide therapeutics, diagnostic and therapeutic targets, SNPs, antisense nucleic acids and GMOs.
Kate has considerable experience of drafting patent applications and developing IP filing strategies in the life sciences field. Kate co-ordinates global patent portfolios for spin out companies and international corporations. She has a substantial prosecution practice and is highly experienced in acting before the European Patent Office in prosecution, opposition and appeal matters, including attending oral hearings.
Kate regularly provides FTO advice and has particular in-depth knowledge of the complexities associated with the bio similar arena. She has extensive experience in conducting due diligence, including performing patentability and validity analysis, in respect of pharmaceutical and life sciences technologies, with a particular focus on peptide therapeutic production patents.
Kate is a direct entrant to the profession, joining HGF in 2000 after graduating from the University of Newcastle-upon-Tyne with a BSc in Genetics and an MSc in Industrial Biotechnology. She became a partner of the firm in 2009.